Regeneron Acquires 23andMe, Samsung's $100M AI Bet, and AI's Role in Drug Discovery - Life AI Weekly #19

Hi there,

In this edition of Life AI Weekly, we're diving into the latest advancements in healthcare and life sciences AI. GATC Health Corp has published a paper highlighting the role of AI in drug discovery, showcasing how artificial intelligence is transforming the way new medications are developed. Meanwhile, QI Path has launched an AI platform aimed at managing risks in drug development, a crucial step in ensuring the safety and efficacy of new treatments.

On the business front, Regeneron has acquired 23andMe for $256 million, marking a significant move in the integration of genetic data with AI-driven healthcare solutions. Additionally, Samsung is set to invest $100 million in Exo, a startup focused on AI medical imaging, underscoring the growing interest in AI technologies that enhance diagnostic capabilities. Stay tuned as we explore these stories and more in this week's edition.

DeepSeq.AI and Serna Bio have been awarded the 2025 Astellas Future Innovator Prize, gaining access to MBC BioLabs' facilities and Astellas' expertise. Recovery.com has acquired RedFox AI to integrate conversational technology into its mental health services. Regeneron Pharmaceuticals has acquired 23andMe for $256 million, focusing on genomic data's role in drug development.

GATC Health Corp has released a paper on its Multiomics Advanced Technology™ platform, which aims to enhance drug discovery by improving speed, cost, and accuracy, while reducing animal testing. QI Path has introduced an AI-driven platform to improve risk mitigation and regulatory readiness in the pharmaceutical industry, offering real-time insights into operational risks throughout the drug development process. Qubit Pharmaceuticals has introduced the FeNNix-Bio1 platform, a quantum AI model developed with Sorbonne University, to accelerate drug discovery and reduce costs by enhancing molecular behavior simulations.

Fujitsu and Tokai National Higher Education and Research System have conducted field trials using AI to enhance patient selection for clinical trials in Japan, aiming to address 'drug loss' by improving data structuring. The Veeva Systems Summit in Madrid will bring together over 1,400 biopharma professionals to discuss AI integration in clinical and quality processes.

GATC Health Corp published a paper on the use of AI in drug discovery. QI Path launched an AI platform for managing risks in drug development. Qubit Pharmaceuticals introduced a quantum AI model aimed at enhancing drug discovery processes.

Lunit will present 12 studies on AI in cancer diagnostics at ASCO 2025. RamSoft and Therapixel partner to integrate AI MammoScreen® for better cancer detection. ASCO and Google Cloud launch an AI tool for faster oncology guidelines access.